Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock

It's always a good sign when a company successfully navigates a period of uncertainty with the help of a well-executed plan. For AbbVie, (NYSE: ABBV) it looks like some celebration is in order, because it just resolved one of its most pressing issues of the past few years.Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today.At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 years the immunosuppressive drug has been on the market, it brought in roughly $200 billion in total revenue, being prescribed for a host of ailments from arthritis to Crohn's disease to plaque psoriasis.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool